Re: Merck's PIII Prostate trial, not the one with ZEN-3694, is halted for not showing improvement vs control
posted on
Jan 27, 2023 10:20AM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
My guess is that they hope for better results by dropping the androgen-deprived therapy and adding the BET Bromodomain Inhibitor ZEN-3694.
I hope that's true as well.
Given that the ZEN study also includes both Enzalutamide and Pembrolizumab, why are similar side effects not a possible concern in the ZEN study?